Edition:
United States

Ventripoint Diagnostics Ltd (VPT.V)

VPT.V on TSX Venture Exchange

0.16CAD
3:55pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.16
Open
$0.16
Day's High
$0.16
Day's Low
$0.16
Volume
90,000
Avg. Vol
101,774
52-wk High
$0.40
52-wk Low
$0.10

Latest Key Developments (Source: Significant Developments)

Ventripoint Diagnostics Ltd announces strategic investment
Tuesday, 3 Nov 2015 09:30am EST 

Ventripoint Diagnostics Ltd:Intends to accept a strategic investment from Shanghai YuTian Medical Investment Management Co. Ltd by way of a private placement offering of a total of 9,090,909 units at $0.055 per Unit for total gross proceeds of up to $500,000.Corporation will use the proceeds of private placement for development, commercialization and general working capital.  Full Article

Ventripoint Diagnostics Ltd closes $3,000,000 private placement
Tuesday, 29 Sep 2015 01:29pm EDT 

Ventripoint Diagnostics Ltd:Completed previously-announced, non-brokered private placement of 54,545,454 units at $0.055 per Unit for total gross proceeds of $3,000,000.Corporation will use the proceeds of the Private Placement for development, sales and marketing and general working capital purposes.  Full Article

Ventripoint closes $800,000 private placement financing
Friday, 5 Jun 2015 08:34am EDT 

Ventripoint Diagnostics Ltd:Completes its non-brokered private placement of 14,545,450 units at $0.055 per Unit for gross proceeds of $800,000.00.Each Unit consists of one common share of Ventripoint and one half warrant.Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.  Full Article

Ventripoint Diagnostics announces increase of private placement financing
Tuesday, 2 Jun 2015 09:44am EDT 

Ventripoint Diagnostics:Says it will increase the recently announced non-brokered private placement to up to 14,545,455 units at $0.055 per Unit for total gross proceeds of up to $800,000.Each Unit will consist of one common share of Ventripoint and one half warrant.Each full Warrant will entitle the holder thereof to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.Corporation has received conditional approval of the Offering from the TSX Venture Exchange.Closing of the offering is expected to occur on or about June 4.Net proceeds of the Offering, after deducting the expenses of the Offering, will be used to incur expenditures for: (i) product and service commercialization of the VMS heart analysis system; (ii) for general working capital purposes and (iii) potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics announces $700,000 private placement financing
Thursday, 28 May 2015 08:19am EDT 

Ventripoint Diagnostics:Intends to complete a non-brokered private placement of up to 12,727,272 units at $0.055 per Unit for total gross proceeds of up to $700,000.Each Unit will consist of one common share of Ventripoint and one half warrant.Each full Warrant will entitle the holder thereof to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.Depending on market conditions, the Corporation reserves the right to increase the maximum gross proceeds under the Offering, subject to the approval of the TSX Venture Exchange.  Full Article

VentriPoint Diagnostics Ltd Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Tuesday, 26 May 2015 08:30am EDT 

VentriPoint Diagnostics Ltd:Says it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA") for the expanded Indications for Use of its VMS(TM) product which states.  Full Article

Ventripoint Diagnostics Receives Marketing Clearance From the FDA to Expand the Use of VMS Heart Analysis System
Monday, 25 May 2015 08:01am EDT 

Ventripoint Diagnostics Ltd:Receives Marketing Clearance from the U.S. Food & Drug Administration (FDA) for the expanded Indications for Use of VMS product which states; The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired.  Full Article

Ventripoint announces acceptance notification from US-FDA of Recent 510 Submission
Friday, 27 Mar 2015 08:00am EDT 

Ventripoint Diagnostics Ltd:Announces that it has received Acceptance Review Notification concerning the Company's recent 510(k) submission (see news release March 16, 2015) to the U.S. Food & Drug Administration.Says the Notification confirms that the submission contains all of the necessary elements and information needed to proceed with the substantive review.A lead reviewer has been assigned and the substantive review has begun.US-FDA guidelines mandate that the Company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days.  Full Article

Ventripoint Diagnostics closes $250,000 debenture financing
Thursday, 26 Mar 2015 08:00am EDT 

Ventripoint Diagnostics Ltd:Has completed non-brokered private placement of C$250,000 of convertible debentures.The debentures mature on March 25, 2016 and may be converted by the holder at any time into common shares of the Corporation at a price of $0.06 per common share.Interest is payable on the debentures at an annual rate equal to twelve percent paid in cash on a quarterly basis in arrears.The net proceeds of the Offering, after deducting the expenses of the Offering, will be used to incur expenditures for: product and service commercialization of the VMS(TM) heart analysis system; for general working capital purposes, and potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics Ltd increases financing to $250,000
Tuesday, 24 Mar 2015 11:15am EDT 

Ventripoint Diagnostics Ltd:Says due to an increase in demand, the maximum gross proceeds of the non-brokered private placement of unsecured convertible debentures of the Company has been increased to $250,000.Offering is expected to close on or about March 25, and the Offering is subject to TSX Venture Exchange final acceptance.Debentures issued in connection with the Offering will be subject to a four month and 1 day hold period from the date of issuance of such securities.Debentures will have a maturity date of one year from the date of issuance, and may be converted by the holder at any time following the issuance of the Debentures into common shares of the Company at a price of $0.06 per common share.Debentures shall bear a 12 pct annual simple interest calculated on the principal amount, payable quarterly in arrears in cash.Net proceeds, after deducting the expenses of the Offering, will be used to incur expenditures for: (i) product and service commercialization of the VMS(TM) heart analysis system; and (ii) general working capital purposes and potentially to repay debt and outstanding payables.  Full Article

BRIEF-Ventripoint announces amendment of debentures and extension of private placement

* Ventripoint announces amendment of debentures and extension of private placement Source text for Eikon: Further company coverage:

No consensus analysis data available.